e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Novel strategies for the management of asthma, COPD and airway infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Biopharmaceutical and chemical compatibility of the combination of salbutamol hemisuccinate and methatropium iodide
Tatiana Molostova (Moscow, Russian Federation), Tatiana Molostova, Alexander Chuchalin, Sofia Skachilova, Elena Shilova, Yuriy Kalinin, Tamerlan Balaev, Irina Badygina, Alexander Solovyev
Source:
International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Session:
Novel strategies for the management of asthma, COPD and airway infections
Session type:
Thematic Poster Session
Number:
3943
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tatiana Molostova (Moscow, Russian Federation), Tatiana Molostova, Alexander Chuchalin, Sofia Skachilova, Elena Shilova, Yuriy Kalinin, Tamerlan Balaev, Irina Badygina, Alexander Solovyev. Biopharmaceutical and chemical compatibility of the combination of salbutamol hemisuccinate and methatropium iodide. Eur Respir J 2015; 46: Suppl. 59, 3943
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Chronic dosing effects of propranolol in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Safety and tolerability of acute dosing of beta-blockers in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013
The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD
Source: International Congress 2014 – COPD markers
Year: 2014
In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Inspiratory flow resistance of marketed dry powder inhalers (DPI)
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials
Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies
Year: 2016
Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept